170 related articles for article (PubMed ID: 37569605)
1. Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine.
Khaleel B; Lunenfeld E; Kapelushnik J; Huleihel M
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569605
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte Colony-Stimulating Factor Restored Impaired Spermatogenesis and Fertility in an AML-Chemotherapy Mice Model.
Michailov Y; AbuMadighem A; Lunenfeld E; Kapelushnik J; Huleihel M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681817
[TBL] [Abstract][Full Text] [Related]
3. Effect of Chemotherapy Cytarabine and Acute Myeloid Leukemia on the Development of Spermatogenesis at the Adult Age of Immature Treated Mice.
Khaleel B; Lunenfeld E; Kapelushnik J; Huleihel M
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409373
[TBL] [Abstract][Full Text] [Related]
4. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
5. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G; Kantarjian H; Wang X; Plunkett WK; Gandhi VV; Faderl S; Garcia-Manero G; Ravandi F; Pierce S; Estey EH
Cancer; 2008 Dec; 113(11):3181-5. PubMed ID: 18932257
[TBL] [Abstract][Full Text] [Related]
6. Protection of spermatogenesis against gamma ray-induced damage by granulocyte colony-stimulating factor in mice.
Kim J; Lee S; Jeon B; Jang W; Moon C; Kim S
Andrologia; 2011 Apr; 43(2):87-93. PubMed ID: 21382061
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
8. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
11. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
15. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
17. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
Kang KW; Kim DS; Lee SR; Sung HJ; Kim SJ; Choi CW; Kim BS; Park Y
Leuk Res; 2017 Jun; 57():1-8. PubMed ID: 28231491
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
19. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Shen YJ; Zhang Y; Chang J; Wang HF; Ye XN; Zhu L; Jin J; Zhu HH
Ann Hematol; 2023 Jul; 102(7):1731-1738. PubMed ID: 37145324
[TBL] [Abstract][Full Text] [Related]
20. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
